Overview

ReCode Therapeutics is a clinical-stage biotechnology company specializing in genetic medicines, particularly through the use of mRNA and gene correction therapeutics. The company's proprietary Selective Organ Targeting (SORT) lipid nanoparticle platform allows for precise and targeted delivery of genetic therapies directly to the organs and tissues affected by various diseases. Their lead programs aim to treat rare genetic conditions, including primary ciliary dyskinesia and cystic fibrosis associated with specific gene mutations. ReCode is actively expanding its focus to develop therapies for a broader range of genetic disorders across various bodily systems. Committed to advancing the next generation of genetic medicines, ReCode Therapeutics promotes a collaborative culture that values innovation, integrity, and a dedication to improving patient outcomes through cutting-edge scientific advancements.